| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
TNF-α is a proinflamatory cytokine, plays a pivotal role in the inflammatory reaction. Its precursor is cleaved by a metalloprotease named TNF-α-converting enzyme(TACE) to generate the mature TNF-α. The aim of this study is to generate a potent anti-inflammatory drug, TACE inhibitor and epigallocatechin 3 gallate(EGCG) to periodontitis where TNFα is thought to be pathologically indicated. TACE immunopositively localized mainly in macrophages and gingival fibroblast in inflamed human gingival tissues. The TACE inhibitor and EGCG eliminated kinetics of LPS-induced TNF-α secretion in a dose-dependent manner by ELISA. Furthermore, EGCG showed more strong inhibitory effect under high glucose conditions. TACE reduced alveolar bone loss in a rat model of P. gingivalis-induced periodontitis. TACE inhibitor and EGCG appear to be an attractive target for treating human periodontitis.
|
